Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28649243 | 0.85 | EPHX2 (0.70) | HTR2CEPHX2NR1H4AKR1C3MAPK14 | |
| SCHEMBL3577590 | 0.82 | EPHX2 (0.73) | HTR2CEPHX2NR1H4MAPK14NAMPT | |
| SCHEMBL15651061 | 0.81 | HDAC6 (0.66) | EPHX2NR1H4PPARGALDH1A1HPGD | |
| SCHEMBL15652953 | 0.80 | NR1H4 (0.67) | EPHX2NR1H4PPARGERN1 | |
| SCHEMBL17311280 | 0.78 | MLYCD (0.65) | MAPK14ALDH1A1HPGDCYP2C19CYP1A2 | |
| SCHEMBL15652708 | 0.77 | GAA (0.56) | MAPK14SMN1; SMN2KDM4EROCK2ROCK1 | |
| SCHEMBL27920874 | 0.77 | MAPK14 (0.74) | HTR2CEPHX2NR1H4MAPK14NAMPT | |
| SCHEMBL17339665 | 0.76 | HTR2C (0.63) | HTR2CEPHX2NR1H4MAPK14NAMPT | |
| SCHEMBL20477570 | 0.76 | EPHX2 (0.76) | HTR2CEPHX2NR1H4MAPK14NAMPT | |
| SCHEMBL28844020 | 0.76 | HTR2C (0.62) | HTR2CEPHX2NR1H4MAPK14NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163768-B2 | 4-(4-Hydroxy-3-methyl-phenyl)-2,4,6,7,8,9-hexahydro-pyrazolo[3,4-b]-1,7-naphthyridin-5-one; inhibiting Aurora kinase; inhibiting the proliferation of tumor cells; cancer, psoriasis, leukaemia and lupus | AVENTIS PHARMA S.A.. (FR) | 2012-04-24 | — | — | US | disclosed |
| EP-1910366-B1 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2011-08-24 | — | — | EP | disclosed |
| EP-1746097-B1 | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | AVENTIS PHARMA SA (FR) | 2010-01-13 | — | — | EP | disclosed |
| US-20080261969-A1 | 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them | AVENTIS PHARMA S.A. (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1910366-A2 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007012972-A2 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2007-02-01 | — | — | WO | disclosed |
| EP-1746097-A1 | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | Aventis Pharma S.A. (FR) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261969-A1 | 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them | DPYD, DHPS, QDPR | HTR2C 398/4885EPHX2 308/4885NR1H4 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.